Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$67.72 USD

67.72
3,579,078

-0.14 (-0.21%)

Updated May 17, 2024 04:00 PM ET

After-Market: $67.75 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day

USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.

Indrajit Bandyopadhyay headshot

3 Biotech Stocks With Decent Dividend for a Steady Return

Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

Gilead Sciences (GILD) concluded the recent trading session at $77.56, signifying a -0.31% move from its prior day's close.

GILD or VRTX: Which Is the Better Value Stock Right Now?

GILD vs. VRTX: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights Walmart, NIKE, TJX, Gilead Sciences and Schlumberger

Walmart, NIKE, TJX, Gilead Sciences and Schlumberger are included in this Analyst Blog.

Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?

Smart Beta ETF report for VALQ

Sheraz Mian headshot

Q3 Earnings Scorecard and Analyst Reports for Walmart, Nike & TJX

Today's Research Daily features a real-time scorecard of the Q3 earnings season and new research reports on 16 stocks, including Walmart, Nike & TJX.

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) reachead $79.20 at the closing of the latest trading day, reflecting a +2% change compared to its last close.

Nurix (NRIX) to Report Q3 Earnings: What's in Store?

On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why

The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $75.06, denoting a +0.43% change from the preceding trading day.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $74.10, marking a -1.12% move from the previous day.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $75.53, moving +0.94% from the previous trading session.

AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.

Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients

Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $75.62, moving -0.07% from the previous trading session.

Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates

Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.

Gilead Sciences (GILD) Stock Moves -0.31%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $76.80, marking a -0.31% move from the previous day.

Sanghamitra Saha headshot

Time for Gilead Sciences-Heavy ETFs?

Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.

Nurix (NRIX) Stock Increases 9% in a Month: Here's Why

The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.

Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study

Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.